Return to Home

Elanco Animal Health Incorporated

ELAN

Find Out if You Qualify for a Financial Reward by filling out the form below.

Elanco Animal Health Incorporated Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Elanco issued a press release on June 27, 2024, “announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro. The press release stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024. The Company had previously set a launch timeline for the third quarter of 2024. The press release also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, while the Company had previously set an approval timeline for the third quarter of 2024. Following this news, Elanco’s stock price dropped 11% the same day.

Find More Cases

Ticker Symbol Company Name Join Deadline
APLT Applied Therapeutics, Inc. February 18, 2025 Join
BIOA BioAge Labs, Inc. March 10, 2025 Join
PCRX Pacira BioSciences, Inc. March 14, 2025 Join
NVO Novo Nordisk A/S March 25, 2025 Join
GO Grocery Outlet Holding Corp. March 31, 2025 Join
NEM Newmont Corporation April 01, 2025 Join
GSK GSK plc April 07, 2025 Join
NTLA Intellia Therapeutics, Inc. April 14, 2025 Join